Purpose

Given the need for a more sensitive pathogen detection test in patients with immunocompromised pneumonia, this study will evaluate the performance of the Karius Test, a novel NGS blood test for the diagnosis of infectious diseases. We will compare the performance of the Karius Test to the results of microbiologic tests obtained as part of usual care for immunocompromised patients undergoing evaluation for suspected pneumonia.

Conditions

Eligibility

Eligible Ages
Between 18 Years and 80 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Subjects must meet all of the criteria in Section A and all of the criteria in either Section B, Section C or Section D. Section A: 1. Patient is ≥ 18 years of age. 2. Is currently admitted to the hospital. 3. Has a suspected infectious pneumonia warranting diagnostic evaluation and treatment. 4. Has undergone a diagnostic bronchoscopy for the evaluation of microbiologic etiology of pneumonia within 1 day prior to or has a scheduled bronchoscopy within 5 days following enrollment. 5. Patient or patient's Legally Authorized Representative (LAR) has provided consent for the study. Section B: 1. Has one of the following hematologic malignancies: Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Lymphoma (any type), Multiple Myeloma (MM) or malignant transformation of Chronic Lymphocytic Leukemia (CLL/SLL). 2. Are immunocompromised defined as having at least one of the following: 1. Received chemotherapy within the last 45 days. 2. A relapse of hematologic malignancy for which chemotherapy treatment is anticipated within the next 45 days. 3. ANC<500 for a minimum of 14 days and within 8 weeks prior to enrollment. Section C: 1. Has undergone autologous hematopoietic stem cell transplantation (e.g. bone marrow transplantation) for one of the following hematologic malignancies: Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Lymphoma (any type), or Multiple Myeloma (MM);), or malignant transformation of Chronic Lymphocytic Leukemia (CLL/SLL). 2. Are immunocompromised defined as having at least one of the following: 1. Undergone autologous hematopoietic stem cell transplantation (HSCT) within the past 6 months. 2. Received chemotherapy within the last 45 days. 3. A relapse of hematologic malignancy for which chemotherapy treatment is anticipated within the next 45 days. Section D: 1. Has undergone allogeneic hematopoietic stem cell transplantation (e.g., bone marrow transplantation) for any clinical indication. 2. Are immunocompromised defined as having at least one of the following: 1. Has undergone hematopoietic stem cell transplantation (HCST) within the past 1 year. 2. Has active graft versus host disease (GVHD) requiring immunosuppressive pharmacologic treatment.

Exclusion Criteria

  1. Patient is moribund and, in the opinion of the treating physician, is not expected to survive >24 hours beyond the time of potential study enrollment visit. 2. Microbiologic etiology of index pneumonia event has already been identified per local Standard of Care testing. 3. Patient was previously enrolled in this study. 4. Patient has any condition that, in the opinion of the treating physician, will prevent the patient from completing the study. (Note: a qualified patient may still enroll in the study if they decline to have exploratory research sample collected.) 5. Patient is positive for SARS-COV-2 by any molecular testing within the 14 days prior to enrollment.

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Intent-to-Diagnose Population All subjects enrolled in the study that have at least one Karius Test with a valid result
  • Diagnostic Test: Karius Test
    Karius Test for detection of microbial cell free DNA (mcfDNA) in plasma

Recruiting Locations

Tulane Section of Infectious Disease
New Orleans, Louisiana 70112
Contact:
Alfred Luk, MD
504-988-7316
aluk@tulane.edu

More Details

Status
Recruiting
Sponsor
Karius, Inc.

Study Contact

Asim Ahmed, MD
650-409-5007
asim.ahmed@kariusdx.com

Detailed Description

Pneumonia is a major cause of morbidity and mortality in highly immunocompromised individuals such as patients with hematologic malignancies and/or hematopoietic stem cell transplant. These patients can be infected by a broad range of potential pathogens, including viral, bacterial, and fungal etiologies and sometimes with multiple pathogens simultaneously. Diagnostic testing often fails to identify a microbial etiology for lower respiratory illness even with bronchoalveolar lavage (BAL). In fact, culture methods, PCR, and antigen testing on BAL samples yields a positive result only 30-67% of the time. Additionally, Idiopathic Pulmonary Syndrome (IPS), a non-infectious pulmonary complication of transplant, can have many overlapping symptoms with infectious pneumonia. Treatment for IPS is administration of steroids which can exacerbate infections. Given these reasons, there is a need for better diagnostics to aid in the management of immunocompromised patients with pneumonia. Karius has developed a microbial cell-free plasma next-generation sequencing test for pathogen detection capable of detecting >1,000 organisms including DNA viruses, bacteria, yeasts, molds, and other eukaryotic pathogens. The test is performed in a CLIA-certified/CAP-accredited laboratory with results typically provided within one day from sample receipt. Given the need for a more sensitive diagnostic test for pneumonia in this population, we are evaluating the performance of the Karius Test for pathogen detection.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.